MEDICLIN AG (MED.DE) Stock Fundamental Analysis
FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR
Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 26 industry peers in the Health Care Providers & Services industry. MED has an excellent profitability rating, but there are some minor concerns on its financial health. MED is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
MED had positive earnings in the past year.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED has a better Return On Assets (2.91%) than 65.38% of its industry peers.
MED has a Return On Equity of 11.67%. This is in the better half of the industry: MED outperforms 73.08% of its industry peers.
MED has a better Return On Invested Capital (5.78%) than 69.23% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 5.89%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(5.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.91% | ||
| ROE | 11.67% | ||
| ROIC | 5.78% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED has a Profit Margin of 3.41%. This is in the better half of the industry: MED outperforms 69.23% of its industry peers.
In the last couple of years the Profit Margin of MED has grown nicely.
MED has a Operating Margin (7.13%) which is in line with its industry peers.
MED's Operating Margin has improved in the last couple of years.
MED has a Gross Margin of 83.54%. This is amongst the best in the industry. MED outperforms 80.77% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.13% | ||
| PM (TTM) | 3.41% | ||
| GM | 83.54% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
Compared to 5 years ago, MED has about the same amount of shares outstanding.
Compared to 1 year ago, MED has an improved debt to assets ratio.
2.2 Solvency
MED has an Altman-Z score of 1.64. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
MED has a Altman-Z score (1.64) which is in line with its industry peers.
MED has a debt to FCF ratio of 13.36. This is a negative value and a sign of low solvency as MED would need 13.36 years to pay back of all of its debts.
With a Debt to FCF ratio value of 13.36, MED perfoms like the industry average, outperforming 42.31% of the companies in the same industry.
A Debt/Equity ratio of 1.92 is on the high side and indicates that MED has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.92, MED is doing worse than 65.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | 13.36 | ||
| Altman-Z | 1.64 |
ROIC/WACC1.23
WACC4.69%
2.3 Liquidity
MED has a Current Ratio of 1.81. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.81, MED is doing good in the industry, outperforming 76.92% of the companies in the same industry.
A Quick Ratio of 1.76 indicates that MED should not have too much problems paying its short term obligations.
MED has a Quick ratio of 1.76. This is amongst the best in the industry. MED outperforms 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 541.24% over the past year.
MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
Looking at the last year, MED shows a decrease in Revenue. The Revenue has decreased by -1.47% in the last year.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)541.24%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%88.47%
Revenue 1Y (TTM)-1.47%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%0.33%
3.2 Future
Based on estimates for the next years, MED will show a small growth in Earnings Per Share. The EPS will grow by 6.48% on average per year.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.78 indicates a rather cheap valuation of MED.
Based on the Price/Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
MED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.35.
Based on the Price/Forward Earnings ratio of 6.05, the valuation of MED can be described as very cheap.
Based on the Price/Forward Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.78 | ||
| Fwd PE | 6.05 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MED indicates a rather cheap valuation: MED is cheaper than 96.15% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED indicates a rather cheap valuation: MED is cheaper than 80.77% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.42 | ||
| EV/EBITDA | 3.43 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)0.28
EPS Next 2Y12.62%
EPS Next 3Y6.48%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.35%. Purely for dividend investing, there may be better candidates out there.
MED's Dividend Yield is a higher than the industry average which is at 2.74.
Compared to an average S&P500 Dividend Yield of 2.40, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.35% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
FRA:MED (6/19/2025, 7:00:00 PM)
3.18
+0.06 (+1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.7%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap151.05M
Analysts83.33
Price Target4.79 (50.63%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.35% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.94%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)26.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.78 | ||
| Fwd PE | 6.05 | ||
| P/S | 0.2 | ||
| P/FCF | 4.42 | ||
| P/OCF | 1.88 | ||
| P/B | 0.68 | ||
| P/tB | 0.76 | ||
| EV/EBITDA | 3.43 |
EPS(TTM)0.55
EY17.3%
EPS(NY)0.53
Fwd EY16.52%
FCF(TTM)0.72
FCFY22.64%
OCF(TTM)1.69
OCFY53.3%
SpS16.12
BVpS4.71
TBVpS4.19
PEG (NY)0.28
PEG (5Y)0.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.91% | ||
| ROE | 11.67% | ||
| ROCE | 7.45% | ||
| ROIC | 5.78% | ||
| ROICexc | 7.6% | ||
| ROICexgc | 7.95% | ||
| OM | 7.13% | ||
| PM (TTM) | 3.41% | ||
| GM | 83.54% | ||
| FCFM | 4.47% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score6
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | 13.36 | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 90.73% | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | 2.42 | ||
| Cash Conversion | 76.2% | ||
| Profit Quality | 131.16% | ||
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | 1.64 |
F-Score6
WACC4.69%
ROIC/WACC1.23
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)541.24%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%88.47%
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.47%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%0.33%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y195.75%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y276.49%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y107.99%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%